>

WEBINARS

RSS
>

MEETINGS / EVENTS

RSS
>

FDA MEDWATCH ALERTS

RSS

January 12, 2012

Respironics, Inc. Trilogy 100 Ventilators: Class I Recall - Device May Stop Delivering Therapy to Patient

Summary:

FDA notified health care professionals of the Class 1 recall of this product due to a manufacturing issue can stop delivering therapy to the patient. Part of the blower that circulates air and other gases through the ventilator may move out of position and cause the device to alarm.  Failure to respond could result in the potential for harm or death of a ventilator-dependent patient.

January 12, 2012

Bedford Laboratories Vecuronium Bromide And Polymyxin B For Injection USP For Injection: Recall - Glass Particles

Summary:

Bedford Laboratories issued guidance on the nationwide voluntary product recalls originally issued on August 2, 2011. The recalls were initiated after the discovery of a visible glass particle in a limited number of vials within the lots listed.

January 09, 2012

Endo Pharmaceuticals Opiate Products by Novartis Consumer Health: Public Health Advisory - Potential Safety Risk

Summary:

FDA is advising health care professionals and patients of a potential problem with opiate products manufactured and packaged for Endo Pharmaceuticals by Novartis Consumer Health at its Lincoln, Nebraska manufacturing site.

>

ASA FEATURED PRODUCT

Self-Education and Evaluation (SEE) Program

SKU: 30701-12CE

... Read more »

Single Copies, Member Price: $300

ASA Regulatory Comment Letters

 

12-12-11 - ASA Urges CMS Revise Proposed Rules Changes on Conditions of Participation and More

12-07-11 - ASA Comment Letter on Draft Blueprint for Prescriber Education Under Opioid REMS

09-27-11 - ASA Letter to MEDPAC Regarding Proposed SGR Changes

08-31-11 ASA Comment Letter on 2012 CMS Physician Schedule Proposed Rule 

08-11-11 - ASA Joins Surgical Quality Alliance Comment Letter on Medicare Claims Data Rule

07-27-11 -  ASA Submits Comments to CMS in Regard to the Agency's NPRM on the Five Year Review

07-12-11 -  ASA Details How DEA Can Help Alleviate Drug Shortages in Comment Letter to DOJ

07-06-11 - ASA Expresses Concern to CMS over Rejection of RUC Recommendations

06-03-11 - ASA Responds to Accountable Care Organization Proposed Rule  

05-31-11 -  ASA Responds to FTC's Proposed Statement on ACO Antitrust Enforcement

02-24-11 - ASA Submits Comments to OIG on Company Model

02-18-11 - ASA Submits Comments to CMS Regarding Electronic Health Record Meaningful Use Requirements

01-03-11 - ASA Submits Comments to CMS FY2011 Physician Fee Schedule Final Rule

08-24-10 - ASA Submits Comments to CMS FY2011 Physician Fee Schedule Proposed Rule

03-15-10 -  ASA HIT Meaningful Use Comments to CMS

01-18-10 - ASA Submits Letter to CMS on Hospital Interpretive Guidelines

01-04-10 - ASA Submits Comment Letter to CMS on CY 2010 PFS Final Rule

08-26-09 - ASA submits comment letter to CMS for 2010 Physician Fee Schedule

08-21-09 - ASA submits comment letter to DEA regarding placement of Fospropofol into Schedule IV

07-10-09 - ASA Submits Comments to FDA on Opioid REMS

05-28-09 - ASA Comments to the FDA regarding SEDASYS

04-21-09 - ASA signs joint letter from Surgical Quality Alliance (SQA) regarding 2010 PQRI

03-12-09- ASA signs joint letter to CMS regarding Recovery Audit Contractor (RAC) program

02-27-09 - ASA signs joint letter to FTC regarding “Red Flags Rule”

01-05-09 -ASA joint letter to MedPAC regarding 2010 physician update

12-23-08 - ASA comments to CMS regarding “Never Events”

10-15-08 - ASA comments to CMS regarding transition to Version 5010 and ICD-10